Results 61 to 70 of about 1,426,440 (199)

Left main bronchus compression due to main pulmonary artery dilatation in pulmonary hypertension: two case reports [PDF]

, 2015
Pulmonary arterial dilatation associated with pulmonary hypertension may result in significant compression of local structures. Left main coronary artery and left recurrent laryngeal nerve compression have been described.
Declan P. O'Regan, Gin-Sing, W, Ben Ariff, Wendy Gin‐Sing, Davies, R, Rachel Davies, Jaijee, SK, Gibbs, JS, Shareen K. Jaijee, J. Simon R. Gibbs, Howard, L, Ariff, B, Luke Howard, O'Regan, DP   +13 more
core   +1 more source

Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America

, 2022
Treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in Latin America differs between countries, with regard to disease etiology, health insurance coverage, and drug availability.
Rafael Conde, Restrepo‐Jaramillo, Ricardo, Cáneva, Jorge, Mauricio Orozco‐Levi, Luciano Melatini, Orozco‐Levi, Mauricio, Jorge Cáneva, Diez, Mirta, Mirta Diez, Tomás Pulido, Valdéz, Héctor, Manuel C. Pacheco Gallego, Nayeli Zayas, Ricardo Restrepo‐Jaramillo, Carlos Jardim, Melatini, Luciano, Jardim, Carlos, Pacheco-Gallego, Manuel C., Caio Fernandes, Fernandes, Caio, Pacheco Gallego, Manuel C., Héctor Valdéz, Zayas, Nayeli, Conde, Rafael, Pulido, Tomás   +24 more
core   +1 more source

Tadalafil in patients with chronic obstructive pulmonary disease:a randomised, double-blind, parallel-group, placebo-controlled trial [PDF]

, 2014
Background: Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality of life in patients with idiopathic pulmonary arterial hypertension.
Lipworth, Brian J., Struthers, Allan D., Hopkinson, Pippa J., Goudie, Andrew R., Wei, Li   +4 more
core   +1 more source

Pulmonary Hypertension Associated With COVID‐19 Interstitial Lung Disease

Pulmonary Circulation
Ten patients with post‐COVID ILD‐PH are described. This complication occurred only in patients after prolonged intensive care (ICU) admission for invasive mechanical ventilation.
Shreeya Mehta, Sophie Herbert, Konstantinos Dimopoulos, Bhavin Rawal, Benjamin Garfield, Melissa Heightman, Kate Myall, Bhashkar Mukherjee, Carl Harries, Heba Nashat, Colm McCabe, Anand Devaraj, Simon Bax, Gisli Jenkins, Athol U. Wells, Peter George, Elisabetta Renzoni, S. John Wort, Laura C. Price   +18 more
doaj   +1 more source

Nitric oxide activates AMPK by modulating PDE3A in human pulmonary artery smooth muscle cells

Physiological Reports, 2020
Phosphodiesterase 3 (PDE3), of which there are two isoforms, PDE3A and PDE3B, hydrolyzes cAMP and cGMP—cyclic nucleotides important in the regulation of pulmonary vascular tone.
Julie Dillard, Xiaomei Meng, Leif Nelin, Yusen Liu, Bernadette Chen   +4 more
doaj   +1 more source

Bayesian Inference Associates Rare KDR Variants with Specific Phenotypes in Pulmonary Arterial Hypertension

, 2021
Background: Approximately 25% of patients with pulmonary arterial hypertension (PAH) have been found to harbor rare mutations in disease-causing genes. To identify missing heritability in PAH, we integrated deep phenotyping with whole-genome sequencing ...

core   +1 more source

Pulmonary Hypertension

Deutsches Ärzteblatt international, 2017
About 1% of adults suffer from pulmonary hypertension (PH). The various types of PH differ widely with respect to their incidence, clinical significance, and treatment.Selective review of the literature in association with a consensus conference.Pulmonary hypertension is divided into five major categories.
Marius M, Hoeper, Hossein-Ardeschir, Ghofrani, Ekkehard, Grünig, Hans, Klose, Horst, Olschewski, Stephan, Rosenkranz   +5 more
openaire   +2 more sources

Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

Arthritis Research & Therapy
Background In the EDITA trial, patients with systemic sclerosis (SSc) and mild pulmonary vascular disease (PVD) treated with ambrisentan had a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP ...
Panagiota Xanthouli, Paul Uesbeck, Hanns-Martin Lorenz, Norbert Blank, Christina A. Eichstaedt, Satenik Harutyunova, Benjamin Egenlauf, Jerry G. Coghlan, Christopher P. Denton, Ekkehard Grünig, Nicola Benjamin   +10 more
doaj   +1 more source

Pediatric Pulmonary Hypertension

Journal of the American College of Cardiology, 2013
Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is associated with significant morbidity and mortality. In the majority of pediatric patients, PH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease.
Ivy, D Dunbar, Abman, Steven H, Barst, Robyn J, Berger, Rolf M F, Bonnet, Damien, Fleming, Thomas R, Haworth, Sheila G, Raj, J Usha, Rosenzweig, Erika B, Schulze Neick, Ingram, Steinhorn, Robin H, Beghetti, Maurice   +11 more
openaire   +6 more sources

Cellular senescence in adult pulmonary hypertension: current state and future challenges

European Respiratory Review
Pulmonary hypertension (PH) is a life-threatening disease increasingly being diagnosed in the elderly population, marked by vascular injury, excessive vasoconstriction and progressive remodelling of the pulmonary arteries (PAs).
Sarah-Eve Lemay, Yukimitsu Kuwabara, Sébastien Bonnet, François Potus, Steeve Provencher, Serge Adnot, Olivier Boucherat   +6 more
doaj   +1 more source